Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer

被引:0
作者
Szatkowski, Wiktor [1 ]
Blecharz, Pawel [1 ]
Mitus, Jerzy W. [2 ,3 ]
Jasiowka, Marek [4 ]
Luczynska, Elzbieta [5 ]
Jakubowicz, Jerzy [6 ]
Byrski, Tomasz [7 ,8 ]
机构
[1] Maria Sklodowska Curie Mem Inst Oncol, Ctr Oncol, Dept Gynaecol Oncol, Krakow Branch, Ul Garncarska 11, PL-31115 Krakow, Poland
[2] Maria Sklodowska Curie Mem Inst Oncol, Krakow Branch, Ctr Oncol, Dept Surg Oncol, Ul Garncarska 11, PL-31115 Krakow, Poland
[3] Jagiellonian Univ, Coll Med, Dept Anat, Ul Garncarska 11, PL-31034 Krakow, Poland
[4] Maria Sklodowska Curie Mem Inst Oncol, Dept Med Oncol, Krakow Branch, Ul Garncarska 11, PL-31115 Krakow, Poland
[5] Maria Sklodowska Curie Mem Inst Oncol, Dept Radiol, Ctr Oncol, Krakow Branch, Ul Garncarska 11, PL-31115 Krakow, Poland
[6] Maria Sklodowska Curie Mem Inst Oncol, Dept Radiotherapy, Ctr Oncol, Krakow Branch, Ul Garncarska 11, PL-31115 Krakow, Poland
[7] Pomeranian Med Univ, Int Hereditary Canc Ctr, Dept Genet & Pathol, Ul Polabska 4, PL-70115 Szczecin, Poland
[8] Pomeranian Med Univ, Clin Oncol, Ul Polabska 4, PL-70115 Szczecin, Poland
关键词
Ovarian cancer; BRCA1; Prognostic factors; BRCA2; MUTATIONS; SERUM CA125; PHASE-II; SURVIVAL; CHEMOTHERAPY; WOMEN; FEATURES; CARCINOMA; SURGERY; TRIAL;
D O I
10.1186/s13053-015-0041-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Treatment outcomes appear to be better for ovarian cancer (OC) patients carrying the BRCA1/2 germline mutation than for patients with sporadic OC. However, most published data are for North American, British and Jewish populations. There have been very few studies on treatment outcomes in Central and Eastern European patients with OC. The aim of this study was to analyse prognostic factors in Polish patients with BRCA1-dependent OC (BRCA1-OC). Methods: The records of patients with OC treated with surgery and chemotherapy at the Centre of Oncology in Krakow, Poland, between 2004 and 2009 were reviewed. Based on family history, a group of 249 consecutive patients fulfilling the criteria for risk of hereditary OC were selected and tested for the germline BRCA1 mutation. Response to combination therapy (surgery and chemotherapy) in the BRCA1-OC group was assessed based on clinical examination, imaging and serum CA125. Results: Germline BRCA1 mutations were detected in 69 of the 249 patients, but three of these patients failed to complete the study. Finally, 66 patients with BRCA1-OC were included in the study group. The median age of the study patients was 49.5 years. All had undergone primary or interval cytoreductive surgery and chemotherapy. Progression occurred in 48 (72.7 %) of the 66 patients and median time to progression was 20 months. The 5-year overall survival rate in was 43.9 % and median survival time was 32.3 months. On multivariate analysis, the endometrial subtype of OC and serum CA125 < 12.5 U/ml at the end of treatment were independent, positive prognostic factors for 5-year overall survival. Conclusion: Prognostic factors for favourable treatment outcomes in Polish patients with BRCA1-OC do not appear to differ from those in patients with sporadic OC. The incidence of the endometrial subtype of OC was relatively high (34.9 %) among women in the study. This was unexpected and has not been reported previously. This subtype of OC was an independent prognostic factor for favourable treatment outcomes.
引用
收藏
页数:6
相关论文
共 29 条
[1]   Prognostic factors of stage IV epithelial ovarian cancer: A multicenter retrospective study [J].
Akahira, JI ;
Yoshikawa, H ;
Shimizu, Y ;
Tsunematsu, R ;
Hirakawa, T ;
Kuramoto, H ;
Shiromizu, K ;
Kuzuya, K ;
Kamura, T ;
Kikuchi, Y ;
Kodama, S ;
Yamamoto, K ;
Sato, S .
GYNECOLOGIC ONCOLOGY, 2001, 81 (03) :398-403
[2]   CA125 AS A SERUM MARKER FOR POOR PROGNOSIS IN OVARIAN MALIGNANCIES [J].
ALVAREZ, RD ;
TO, A ;
BOOTS, LR ;
SHINGLETON, HM ;
HATCH, KD ;
HUBBARD, J ;
SOONG, SJ ;
POTTER, ME .
GYNECOLOGIC ONCOLOGY, 1987, 26 (03) :284-289
[3]   Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer [J].
Bolton, Kelly L. ;
Chenevix-Trench, Georgia ;
Goh, Cindy ;
Sadetzki, Siegal ;
Ramus, Susan J. ;
Karlan, Beth Y. ;
Lambrechts, Diether ;
Despierre, Evelyn ;
Barrowdale, Daniel ;
McGuffog, Lesley ;
Healey, Sue ;
Easton, Douglas F. ;
Sinilnikova, Olga ;
Benitez, Javier ;
Garcia, Maria J. ;
Neuhausen, Susan ;
Gail, Mitchell H. ;
Hartge, Patricia ;
Peock, Susan ;
Frost, Debra ;
Evans, Gareth ;
Eeles, Rosalind ;
Godwin, Andrew K. ;
Daly, Mary B. ;
Kwong, Ava ;
Ma, Edmond S. K. ;
Lazaro, Conxi ;
Blanco, Ignacio ;
Montagna, Marco ;
D'Andrea, Emma ;
Nicoletto, Maria Ornella ;
Johnatty, Sharon E. ;
Krueger, Susanne ;
Jensen, Allan ;
Hogdall, Estrid ;
Goode, Ellen L. ;
Fridley, Brooke L. ;
Loud, Jennifer T. ;
Greene, Mark H. ;
Mai, Phuong L. ;
Chetrit, Angela ;
Lubin, Flora ;
Hirsh-Yechezkel, Galit ;
Glendon, Gord ;
Andrulis, Irene L. ;
Toland, Amanda E. ;
Senter, Leigha ;
Gore, Martin E. ;
Gourley, Charlie ;
Michie, Caroline O. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04) :382-390
[4]   Clinicopathologic features of BRCA-linked and sporadic ovarian cancer [J].
Boyd, J ;
Sonoda, Y ;
Federici, MG ;
Bogomolniy, F ;
Rhei, E ;
Maresco, DL ;
Saigo, PE ;
Almadrones, LA ;
Barakat, RR ;
Brown, CL ;
Chi, DS ;
Curtin, JP ;
Poynor, EA ;
Hoskins, WJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (17) :2260-2265
[5]  
Buller RE, 2002, CLIN CANCER RES, V8, P1196
[6]   Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer [J].
Byrski, Tomasz ;
Dent, Rebecca ;
Blecharz, Pawel ;
Foszczynska-Kloda, Malgorzata ;
Gronwald, Jacek ;
Huzarski, Tomasz ;
Cybulski, Cezary ;
Marczyk, Elzbieta ;
Chrzan, Robert ;
Eisen, Andrea ;
Lubinski, Jan ;
Narod, Steven A. .
BREAST CANCER RESEARCH, 2012, 14 (04)
[7]   Improved survival in women with BRCA-associated ovarian carcinoma [J].
Cass, I ;
Baldwin, RL ;
Varkey, T ;
Moslehi, R ;
Narod, SA ;
Karlan, BY .
CANCER, 2003, 97 (09) :2187-2195
[8]   Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer:: The national Israeli study of ovarian cancer [J].
Chetrit, Angela ;
Hirsh-Yechezkel, Galit ;
Ben-David, Yehuda ;
Lubin, Flora ;
Friedman, Eitan ;
Sadetzki, Siegal .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) :20-25
[9]  
Cox DR, 1977, BRIT J CANCER, V35, P1
[10]   BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer [J].
Dann, Rebecca Byler ;
DeLoia, Julie A. ;
Timms, Kirsten M. ;
Zorn, Kristin K. ;
Potter, Jennifer ;
Flake, Darl D., II ;
Lanchbury, Jerry S. ;
Krivak, Thomas C. .
GYNECOLOGIC ONCOLOGY, 2012, 125 (03) :677-682